Non-anemic Iron Deficiency
Conditions
Keywords
Non-anemic Iron Deficiency, Iron Supplementation
Brief summary
Healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. The investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses of iron supplementation.
Detailed description
The primary purpose of this clinical trial is to evaluate the impact of a low-dose iron dietary supplement on markers of iron status among a sample of premenopausal women that are iron-deficient without anemia. This study will also assess the incidence of mild adverse events (constipation, nausea, etc.) that are relatively common with other over the counter iron dietary supplements and that the investigators hypothesize will be reduced with this lower-dose formulation.
Interventions
DIETARY_SUPPLEMENTBlood Builder®/Iron Response®
The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it. One tablet will be taken once a day offering a total daily serving of: * 15 mg of Vitamin C * 400 mcg of Folate * 30 mcg Vitamin of B-12 * 26 mg of Iron * 125 mg of Beet Root
Sponsors
University of Maryland, Baltimore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Pre-menopausal 2. Iron deficient without anemia (serum ferritin concentration \< 20 ug/L and a hemoglobin concentration \> 120 g/L) 3. Agree to continue with current diet and any dietary supplements 4. Able to understand and write English 5. Voluntarily consent to the study and understand its nature and purpose including potential risks and side effects
Exclusion criteria
1. Daily supplementation of another iron supplement (other than multivitamin) currently or within past 2 weeks 2. Pregnant or breastfeeding females 3. History of alcohol, drug, or medication abuse 4. Known allergies to any substance in the study product 5. Donated blood in the past month or plan to do so at any time during the 8-week trial 6. Current diagnosis of inflammatory bowel disease (Crohn's or Ulcerative Colitis) 7. Taking medication that my interfere with the absorption of iron 8. Current tobacco smoker
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Hemoglobin (Hgb) Level | Baseline and study end (8 weeks from baseline) | Marker of iron status |
| Changes in Serum Ferritin (SF) Level | Baseline and study end (8 weeks from baseline) | Marker of iron status |
| Changes in Soluble Transferrin Receptor (sTfR) Level | Baseline and study end (8 weeks from baseline) | Marker of iron status |
| Changes in Total Body Iron Stores | Baseline and study end (8 weeks from baseline) | Marker of iron status |
Secondary
| Measure | Time frame |
|---|---|
| Frequency and severity of self-reported fatigue | Baseline and study end (8 weeks from baseline) |
| Self-reported energy level | Baseline and study end (8 weeks from baseline) |
| Frequency and severity of self-reported constipation | Study end (8 weeks from baseline) |
| Adverse events | Study end (8 weeks from baseline) |
| Supplement compliance assessed using participant daily diary | Study end (8 weeks from baseline) |
| Frequency and severity of self-reported diarrhea | Study end (8 weeks from baseline) |
| Frequency and severity of self-reported nausea | Study end (8 weeks from baseline) |
| Frequency and severity of self-reported vomiting | Study end (8 weeks from baseline) |
Countries
United States
Outcome results
None listed